American Research Institute | Cutler Bay, FL

Research site

(Unclaimed)

Location

18951 SW 106th Ave, Suite B-110, Cutler Bay, Florida, United States of America

Site insights

Top conditions

Top treatments

Ozanimod

Relamorelin

Clazakizumab

Lanifibranor

Linaprazan Glurate

fezolinetant

Eloralintide

OM-85

Muvalaplin

LY3841136

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 17 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Active, not recruiting

NASH - Nonalcoholic Steatohepatitis

Drug: Placebo

Drug: IVA337

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event (CLARITY-CRP)

The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazaki...

Enrolling

Hypertension

Obesity

Drug: Placebo

Drug: Clazakizumab

New

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk (ENLIGHTEN-10)

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overwei...

Begins enrollment this month

Overweight

Obesity

Drug: Eloralintide

Drug: Placebo

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) (MOVE-Lp(a))

The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Placebo

Drug: Muvalaplin

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Active, not recruiting

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo